Journal of Lipid Research, Vol 24, 1595-1604, Copyright © 1983 by Lipid Research, Inc.

ARTICLES

Eicosapentaenoic acid and prostacyclin production by cultured human endothelial cells

AA Spector, TL Kaduce, PH Figard, KC Norton, JC Hoak and RL Czervionke

Human umbilical vein endothelial cells incorporate eicosapentaenoic acid (EPA) when this fatty acid is present in the culture medium. From 30 to 70% of the uptake remains as EPA, and much of the remainder is elongated to docosapentaenoic acid. All of the cellular glycerophospholipids become enriched with EPA and docosapentaenoic acid, with the largest increase in EPA occurring in the choline glycerophospholipids. When this fraction is enriched with EPA, it exhibits a large decrease in arachidonic acid content. Cultures exposed to tracer amounts of [1-14C]linolenic acid in 5% fetal bovine serum convert as much as 17% of the radioactivity to EPA. The conversion is reduced, however, in the presence of either 20% fetal bovine serum or 50 microM linolenic acid. Like arachidonic acid, some newly incorporated EPA was released from the endothelial cells when the cultures were exposed to thrombin. However, as compared with arachidonic acid, only very small amounts of EPA were converted to prostaglandins. Cultures enriched with EPA exhibited a 50 to 90% reduction in capacity to release prostacyclin (PGI2) when subsequently stimulated with thrombin, calcium ionophore A23187, or arachidonic acid. The degree of inhibition was dependent on the time of exposure to EPA and the EPA concentration, and it was not prevented by adding a reversible cyclooxygenase inhibitor, ibuprofen, during EPA supplementation. EPA appears to decrease the capacity of the endothelial cells to produce PGI2 in two ways: by reducing the arachidonic acid content of the cell phospholipid precursor pools and by acting as an inhibitor of prostaglandin production. These findings suggest that regimens designed to reduce platelet aggregation and thrombosis by EPA enrichment may also reduce the capacity of the endothelium to produce PGI2.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Massaro, A. Habib, L. Lubrano, S. D. Turco, G. Lazzerini, T. Bourcier, B. B. Weksler, and R. De Caterina The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC{varepsilon} inhibition PNAS, October 10, 2006; 103(41): 15184 - 15189. [Abstract] [Full Text] [PDF]

				P. Yang, D. Chan, E. Felix, C. Cartwright, D. G. Menter, T. Madden, R. D. Klein, S. M. Fischer, and R. A. Newman Formation and antiproliferative effect of prostaglandin E3 from eicosapentaenoic acid in human lung cancer cells J. Lipid Res., June 1, 2004; 45(6): 1030 - 1039. [Abstract] [Full Text] [PDF]

				T. L. Kaduce, X. Fang, S. D. Harmon, C. L. Oltman, K. C. Dellsperger, L. M. Teesch, V. R. Gopal, J. R. Falck, W. B. Campbell, N. L. Weintraub, et al. 20-Hydroxyeicosatetraenoic Acid (20-HETE) Metabolism in Coronary Endothelial Cells J. Biol. Chem., January 23, 2004; 279(4): 2648 - 2656. [Abstract] [Full Text] [PDF]

				E. D. Thuresson, M. G. Malkowski, K. M. Lakkides, C. J. Rieke, A. M. Mulichak, S. L. Ginell, R. M. Garavito, and W. L. Smith Mutational and X-ray Crystallographic Analysis of the Interaction of Dihomo-gamma -linolenic Acid with Prostaglandin Endoperoxide H Synthases J. Biol. Chem., March 23, 2001; 276(13): 10358 - 10365. [Abstract] [Full Text] [PDF]

				M. G. Malkowski, E. D. Thuresson, K. M. Lakkides, C. J. Rieke, R. Micielli, W. L. Smith, and R. M. Garavito Structure of Eicosapentaenoic and Linoleic Acids in the Cyclooxygenase Site of Prostaglandin Endoperoxide H Synthase-1 J. Biol. Chem., September 28, 2001; 276(40): 37547 - 37555. [Abstract] [Full Text] [PDF]